1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Wet Age-Related Macular Degeneration (Wet AMD) - Epidemiology Forecast to 2030

Wet Age-Related Macular Degeneration (Wet AMD) - Epidemiology Forecast to 2030

  • February 2021
  • 65 pages
  • ID: 6028061
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Wet-Age-related Macular Degeneration (Wet-AMD) – Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Wet-AMD, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Wet-AMD Disease Understanding
Age-related macular degeneration (AMD) is a leading cause of severe, irreversible blindness in developed countries worldwide, profoundly affecting the quality of life of affected individuals. The increase in life expectancy bringing growth in the number of reported cases adds a significant burden on the health care systems with the expensive current standard of care. Wet-AMD is a type of AMD which is characterized by abrupt central vision loss caused by abnormal blood vessels that bleed or leak fluid, which may swell and damage the macula. Wet-AMD, also referred to as neovascular AMD, accounts for roughly 10% of AMD cases, but almost 90% of AMD-related central vision loss. Although 80% of the patients have non-neovascular or atrophic AMD, the disease’s neovascular form is responsible for nearly 90% of the severe, central visual acuity loss associated with AMD.
AMD’s progression leads to loss of central vision, which adversely affects the quality of life. Although AMD’s exact functional pathogenesis is not fully understood, there have been recent improvements in genetic technologies leading to the identification of various polymorphisms that have shown to harbor unique AMD associations.

Wet-AMD Epidemiology
The Wet-AMD epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings
The total prevalent cases of Wet-AMD patients are increasing in 7MM during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Wet-AMD symptoms epidemiology segmented as the Total Prevalent cases of Wet-AMD, Gender-specific cases of Wet-AMD, and Age-specific cases of Wet-AMD. The report includes the prevalent scenario of Wet-AMD symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise - Wet-AMD Epidemiology
The epidemiology segment also provides the Wet-AMD epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total prevalent cases of Wet-AMD associated in 7MM countries were 4,426,968 in 2020.
• As per the estimates, the United States has the largest prevalent population of Wet-AMD.
• Among the EU5 countries, Germany had the highest prevalent cases of Wet-AMD, followed by Italy. On the other hand, Spain had the lowest prevalent cases with 300,552 cases in 2020.

Scope of the Report
• The Wet-AMD report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
• The Wet-AMD Epidemiology Report and Model provide an overview of Wet-AMD’s risk factors and global trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into Wet-AMD’s historical and forecasted patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Wet-AMD.
• The report provides the segmentation of the Wet-AMD epidemiology by diagnosed prevalent cases of Wet-AMD in 7MM.
• The report provides the segmentation of the Wet-AMD epidemiology by Gender-specific prevalent cases of Wet-AMD in 7MM.
• The report provides the segmentation of the Wet-AMD epidemiology by Age-specific prevalent cases of Wet-AMD in 7MM.

Report Highlights

• 11-year Forecast of Wet-AMD epidemiology
• 7MM Coverage
• Total Diagnosed Prevalent Cases of Wet-AMD
• Prevalent Cases according to segmentation: Gender-specific cases of Wet-AMD
• Prevalent Cases according to segmentation: Age-specific cases of Wet-AMD

KOL Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM for the patient population about Wet-AMD?
• What are the key findings of the Wet-AMD epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of Wet-AMD patients across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What are the disease risk, burden, and unmet needs of the Wet-AMD?
• What are the currently available treatments for Wet-AMD?

Reasons to buy
The Wet-AMD epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Wet-AMD market.
• Quantify patient populations in the global Wet-AMD market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Wet-AMD therapeutics in each of the markets covered.
• Understand the magnitude of the Wet-AMD population by its Total Prevalence cases.
• Understand the magnitude of the Wet-AMD population by its Gender-specific cases.
• Understand the magnitude of the Wet-AMD population by its Age-specific cases.
• The Wet-AMD epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Wet-AMD Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
In the case of the United States, as per estimates, approximately 11 to 15 million people in the United States have AMD, and more than 1.7 million Americans have the advanced form of the disease. About 200,000 new cases of wet AMD are diagnosed each year in North America. Due to the aging population, the National Eye Institute estimates that the prevalence of advanced AMD will grow to nearly 3 million by 2020. Wet macular degeneration accounts for approximately 10 percent of cases, but results in 90 percent of legal blindness. This assumption was particularly used to obtain the burden of Wet-AMD among the prevalent AMD population. Age is a prominent risk factor for Age-related macular degeneration. The risk of getting advanced age-related macular degeneration increase from 2% for those ages 50–59 to nearly 30% for those over the age of 75.
A recent study by the European Eye Epidemiology (E3) Consortium collated prevalence data of 14 European population studies and reported the prevalence of any AMD among adults aged 70 years and older to be 16.2% based on the Rotterdam classification. The authors extrapolated the number of Europeans with early and late AMD and predicted almost a doubling of AMD prevalence in Europe until 2040. Yet, until today, we lack pooled European estimates on AMD incidence.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Paroxysmal Nocturnal Hemoglobinuria - Epidemiology Forecast to 2030

  • $ 3750
  • February 2021
  • 75 pages

‘Paroxysmal nocturnal hemoglobinuria (PNH) – Epidemiology Forecast—2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology of PNH in the United States, EU5 ...

  • World
  • Spain
  • Biopharmaceutical
  • Epidemiology
  • Industry analysis
  • Stem Cell Transplantation
  • Mortality Rate

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on